arrow
L

Laura Arenare

University of Naples Federico II
H指数:20
被引数:1,536

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Somatic BRCA1 and BRCA2 detection in Homologous Recombination Deficiency testing: concordance of four sequencing workflows with the Myriad myChoice® companion diagnostic

体细胞BRCA1和BRCA2检测在同源重组缺陷测试中的应用:四种测序工作流与Myriad myChoice®伴随诊断的一致性

2026-06-200
PRE
Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial

多模态泛肿瘤细胞游离DNA分析用于卵巢癌微小残留病灶检测和风险分层:MITO16a/MaNGO-OV2试验结果

2026-02-260
OAAI
CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026-01-010
PRE
Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial

高级别子宫内膜癌中的同源重组修复状态:来自随机、II期MITOEND 3试验的探索性生物标志物分析

2025-12-050
OAAI
Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trial

肿瘤浸润性白细胞作为接受贝伐珠单抗治疗的卵巢癌患者的预后生物标志物:来自IV期MITO16A/MaNGO OV-2临床 trial 的结果

2025-11-170
OAAI
The Impact of body mass index on Survival and Surgical Outcomes in Ovarian Cancer: Insights from the MITO Trials

体重指数对卵巢癌患者生存及手术结果的影响:来自MITO试验的见解

2025-11-010
PRE
Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients

纵向验证PROFFIT问卷以评估癌症患者的财务毒性

2025-10-010
OAAI
Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin plus paclitaxel/avelumab (MITO-END3 trial)

外周单核细胞源性抑制性细胞与单中心接受卡铂联合紫杉醇/阿维单抗治疗子宫内膜癌患者分子亚型的相关性(MITO-END3试验)

2025-04-170
OA
Homologous Recombination Repair Status In Advanced Endometrial Cancer. An Exploratory Biomarker Analysis From The Randomized, Phase II MITO END 3 Trial

高级子宫内膜癌的同源重组修复状态。来自随机、II期MITO END 3试验的探索性生物标志物分析

2025-02-010
PRE
Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial
2025-01-011
OAAI
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid D letrozole in premenopausal hormone receptor-positive early breast cancer patients
2025-01-010
PRE
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study

接受贝伐单抗联合一线化疗的卵巢癌患者的TP53突变和生存率: MITO16A/MaNGO OV-2研究的结果

2024-10-160
OAAI
Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP study
BREAST
IF7.9
2024-10-010
OAAI
Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study (vol 41, 100912, 2024)
2024-09-010
OA
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial
2024-07-010
PRE
Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study (Vol 41, 100912, 2024)
2024-07-010
OA
Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study (vol 41, 100912, 2024)
2024-07-010
OA
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy
2024-07-014
PRE